Combination Products



M. Gropp; Abbott Vascular, Brussels



Caveats

- Complex topics
- Focus mostly on device-drug combinations, but similar considerations apply to other combination products
 - Taken from medical device perspective
- Personal views



Combination Products





Building a Prosperous Asia-Pacific through Free and Open Trade and Investment Promoting the Safe and Efficient Movement of Goods, Services and People through the Asia-Pacific Region



Source: About APEC, APEC Secretariat, 2004





to clothes to communications.

Highlights include -

- APEC economies have improved their governance and are ahead of the rest of the world in this area.
- APEC's Economic and Technical Cooperation is contributing to the reform process.
- The APEC region is meeting the Millennium Development Goals.





Source: APEC At a Glance, APEC Secretariat, 2006





APEC Tokyo 2006 Combination Products and Asian Harmonization; M. Gropp

USA definition:

"... an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is —

- (1) recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them,
- (2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or
- (3) intended to affect the structure or any function of the body of man or other animals, ...



USA definition (continued):

"... and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes." [Emphasis added]



Source: 21 U.S.C. 201(h)

European Union definition:

"... any instrument, apparatus, appliance, material or other article, whether used alone or in combination, including the software necessary for its proper application **intended** by the manufacturer to be used for human beings for the purpose of:

 diagnosis, prevention, monitoring, treatment or alleviation of disease,

- diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap,

- investigation, replacement or modification of the anatomy or of a physiological process,

- control of conception, ...



Source: Council Directive 93/42/EEC of 14 June 1993 concerning medical devices

European Union definition (continued):

"... and which does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means" [Emphasis added]



Source: Council Directive 93/42/EEC of 14 June 1993 concerning medical devices

Japan definition:

(定義) 第2条

この法律で「医療機器」とは、人若しくは動物の疾病の診断、治療若しくは予防に使用されること、又は人若しくは動物の身体の構造若しくは機能に影響を及ぼすことが目的とされている機械器具等であって、政令で定めるものをいう。

"equipments, instruments etc. specified by the government ordinance which are intended for use in the diagnosis, treatment or prevention of disease in humans or animals, or intended to affect the structure and functions of the human or animal body" [Emphasis added]



Source: The Pharmaceutical Affairs Law; Law No. 145, dated Aug. 10, 1960, as amended by Law No. 73, dated June 11, 2003

Global Harmonization Task Force (GHTF) definition:

"... any instrument, apparatus, implement, machine, appliance, implant, *in vitro* reagent or calibrator, software, material or other similar or related article:

a) **intended** by the manufacturer to be used, alone or in combination, for human beings for one or more of the specific purpose(s) of:

- Diagnosis, prevention, monitoring, treatment or alleviation of disease
- **Diagnosis, monitoring, treatment, alleviation** of or compensation for an injury,
- Investigation, replacement, modification, or support of the anatomy or of a physiological process ..."



Source: GHTF/SG1/N29R16:2005; Information Document Concerning the Definition of the Term "Medical Device"

GHTF definition (continued):

- supporting or sustaining life
- control of conception,
- disinfection of medical devices,
- providing information for medical or diagnostic purposes by means of *in vitro* examination of specimens derived from the human body

and

b) which does not achieve its primary intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its intended function by such means" [Emphasis added]



Source: GHTF/SG1/N29R16:2005; Information Document Concerning the Definition of the Term "Medical Device"



Source: US FDA CDRH 2005 Strategic Plan





- Medical devices distinguished from drugs and biological products on basis of intended mode(s) of action
 - Not metabolic, pharmacologic, or immunologic
 - May be assisted by such means
- Internationally harmonised definition exists
 - Not yet uniformly adopted
 - Opportunity for international harmonisation
- No international definition of products that may cross borderlines
 - Opportunity for international harmonisation



Drugs and medical devices differ

Drugs

- Discovered
- Stable formulation developed
- Highly mechanised manufacture
- Consumed by use
- Systemic toxicity
- Large populations of exposure
- Patient may choose to stop use

Medical devices

- Designed
- Constant iterative improvements or changes
- Often manufactured by hand operations
- Available for study after use
- Adverse events most often
 local in nature
- Relatively limited populations of exposure
- Generally not subject to ethnic differences
- Most intended for professional use



Source: S. Alpert, M.D., PhD. (Medtronic Corp.); Asian Harmonization Working Party, Seoul, Sept. 2006 (adapted)

Drugs and medical devices differ

Drugs

- Pure molecules
- Toxicology
- Short half-life in body
- Long market life
- Drug interactions
- Wrong drug/dose
- Clinically studied
- Good Manufacturing practice (cGMP)

Medical devices

- Complex components and assemblages
- Biocompatibility
- Durable
- Rapid product cycles
- Device malfunction
- Use error
- Often bench studied
- Quality management systems (ISO 9000 → ISO 13485)



Source: D. Schultz, US FDA CDRH; Development of New Technology and Challenges to Regulatory Harmonization; APEC 2005, Taipei, Nov. 2005 (adapted)

Addressing unmet clinical needs



Deep brain stimulation – Parkinson's, tremor

Neuroprosthesis – retinal stimulation

Advanced catheter technology – Alzheimer's

Percutaneous valve repair VADs **Diastolic Limiters** Ventricular sourcing Atrial appendage plug AF devices, ablation Tissue engineering RF ablation – oncology Minimally invasive, transcervical, permanent contraception Intravascular temperature mgmt for AMI, stroke





18-Oct-06

APEC

Injectable liquid bone substitute solidifies at body temperature

A bone substitute material that remains liquid at room temperature but solidifies at body temperature has been developed by a team of researchers at the Nara Institute of Science and Technology.

The landmark material solidifies to become part of a bone after being injected into the body while it is a liquid, opening the prospect of treating damaged bones without performing surgery. It can also be used as a kind of cement when artificial joints are affixed to bones.

Led by Masao Tanihara, a professor of biocompatible materials science at the institute, the team was able to create the new material by combining Poly-N-isopropyl acrylamide, a type of resin that is highly sensitive to changes in temperature, with calcium phosphate, a natural substance found in bones.

Mending

How to treat broken bone with new material



Source: The Nikkei Business Daily

The group found that the material quickly solidifies when the temperature is raised to over 33 C (91.4 F).



Source: Nikkei Weekly 20 Feb. 2006









A major application of nanotechnology may be the targeted delivery of drugs to specific organs or tissues, e.g. for the treatment of cancers at their site rather than the use of systemic and often highly toxic chemotherapy

Another possible application could be the delivery to specific sites of coated nanoparticles that could then be heated using intense light thereby destroying diseased tissue and cells





Some researchers postulate that synthetic "respirocytes" could augment oxygen supply to poorly vascularised tissues

Measuring 1 micron in diameter, it has been suggested that these could pump 236 times more oxygen to tissue than a red blood cell

They could also include an onboard nanocomputer and chemical and pressure sensors





An example of human tissue-engineered cartilage intended to replace damaged cartilage as shown in the radiographic image





It is now becoming feasible to inject nano-encapsulated drugs, or metallic or semimetallic particles, into the T-lymphocyte which can be subsequently transported to a tumour site and there released or activated physically by an external source





Osteocytes growing on a spherical biopolymer scaffold (bottom of micrograph). Such products could typically be used in orthopaedic and reconstructive surgery



Combination products

Japan METIS (Medical Engineering Technology Industrial Strategy Consortium)

- Gene chips for diagnosis
- Diagnosis and treatment with molecular imaging
- DDS and target treatment
- Minimally invasive treatment devices
- Bionics medical equipment
- Organ function assist device
- Regenerative medical techniques for bone, cartilage, blood vessels, and cardiac muscles



Converging medical technologies





APEC Tokyo 2006 Combination Products and Asian Harmonization; M. Gropp

Converging medical technologies





What is a "combination product"?

Combinations of different types of regulated products

- Drug medical device
- Medical device biologic
- Drug biologic
- Drug medical device biologic

Combination products may be:

- Physically or chemically combined (e.g., transdermal drug delivery)
- Co-packaged in a kit
- Separate, cross-labeled products (e.g., implantable pumps)



Source: D. Schultz, US FDA CDRH; Development of New Technology and Challenges to Regulatory Harmonization; APEC 2005, Taipei, Nov. 2005

Combination products

- One item composed of two or more products that are subject to different regulatory regimes
- Two or more differently regulated items that must be used together to achieve the intended outcome
 - Often, but not always, packaged together
 - Labelled for required use together
- Often offer unique therapeutic advantages
- A regulatory challenge for regulators and industry



Source: S. Alpert, M.D., PhD. (Medtronic Corp.); Asian Harmonization Working Party, Seoul, Sept. 2006, and US FDA (adapted)

Combination products becoming more common

Combination product applications US FDA





Source: FY 2005 Performance Report to Congress; US FDA Office of Combination Products

What is a "combination product"?

- "A product comprised of two or more regulated components ... that are physically, chemically, or otherwise combined or mixed and produced as a single entity;
- Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products;
- A drug, device, or biological product packaged separately that according to its ... labeling is intended for use only with an ... individually specified, drug, device or biological product where both are required to achieve the intended use, indication, or effect"



Source: US FDA; 21 CFR § 3.2(e)

Combination products

- In many economies, regulatory controls and requirements for drugs, devices, and biological product are similar, but different
 - One approach does not suit all products
- Pre- and post-market requirements differ
- No special type of marketing application for combination products
- Several regulatory authorities or components may have interest and expertise
- Need clear rules for determining regulatory responsibility



Combination products regulatory considerations

- How, and by whom, product will be used
- Additive effects of other components
- Entire life cycle of product should be considered
- Product's most important therapeutic benefit helps determine how to regulate



Combination products regulatory considerations

 Mode of action: "... the means by which a product achieves an intended therapeutic effect or action. ...

"therapeutic" action or effect includes any effect or action of the combination product intended to diagnose, cure, mitigate, treat, or prevent disease, or affect the structure of any function of the body"



Source: US FDA; 21 CFR 3.2 (k)
Combination products regulatory considerations

 Primary mode of action: "... the single mode of action of a combination product that provides the most important therapeutic action of the combination product.

The most important therapeutic action is the mode of action expected to make the greatest contribution to the overall intended therapeutic effects of the combination product"



Determining "primary mode of action"



Source: US FDA Talk Paper, May 6, 2004 regarding proposed rule on combination products (http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01288.html)

Combination products regulatory objectives

- Effective regulation of the combination taking into account each contributing attribute
- Risk-based and proportionate controls
 - Protect patients
 - Promote innovation
- Scientifically appropriate assessments
- Avoid repetitive or unnecessary reviews
- Transparency of jurisdiction determinations, requirements and review pathways
- Timely access of patients and clinicians to these important products



Combination products -- Summary

- Combination products offer therapeutic benefits
- Combination products pose challenges for regulators and industry
- Regulatory differences derive from underlying product differences
- Regulatory requirements and authorisation pathways should be consistent and predictable
- Opportunity for international regulatory harmonisation
- Important challenge for global product development and clinical trials



Asia Regional Medical Device Regulatory Harmonization



M. Gropp; Abbott Vascular, Brussels



Caveats

- Complex topic
- General overview



What is regulatory "harmonization"?

- Progressive convergence over time of regulatory requirements and practices
- Progressive elimination or reduction of technical differences in regulatory requirements

Facilitates global product development and clinical investigations



International medical device regional regulatory harmonization initiatives





APEC Tokyo 2006 Combination Products and Asian Harmonization; M. Gropp



Global Harmonization Task Force (GHTF) History

- Informal grouping of medical device regulators and industry
- Began in 1992
- Canada, European Union, Japan, USA
 - Australia joined in 1993
 - "Founding Members"
 - Other interested countries are "Participating Members"
- Analogous to International Conference on Harmonization (ICH) in pharmaceutical sector





GHTF

Purpose:

".... to encourage convergence in regulatory practices related to ensuring the safety, effectiveness / performance and quality of medical devices, promoting technological innovation and facilitating international trade ..."

Source: GHTF





GHTF

Purpose (cont'd):

".... the primary way in which this is accomplished is via the publication and dissemination of harmonized guidance documents on basic regulatory practices.

These documents can then be adopted / implemented by member national regulatory authorities ..."

 GHTF guidance substantially adopted in Australia, Canada, EU, and Japan

Source: GHTF





GHTF

Purpose (cont'd):

".... GHTF also serves as an information exchange forum through which countries with medical device regulatory systems under development can benefit from the experience of those with existing systems and/or pattern their practices upon those of GHTF founding members."

Source: GHTF









APEC



GHTF guidance documents



50

APEC MEMBER ECONOMIES





Asia: Emerging medical technology regulation





Forces driving medical device regulation in Asia-Pacific region

- Policy objective to protect public health
- Rising public expectations of access to health care
- Rising domestic industry
- Control of trade (import and export)
- Concerns about used/second-hand equipment being placed on local market
- Lending institution interests
 - Opportunity for prospective, rather than retrospective, harmonisation?



Asia-Pacific medical device regional regulatory harmonization initiatives





APEC Tokyo 2006 Combination Products and Asian Harmonization; M. Gropp



Asian Harmonization Working Party (AHWP)

- Formed in 1996-7
- Informal grouping

Regional economy regulators and industry representatives





Asian Harmonization Working Party (AHWP)

Member economies (regulators and industry)

- Brunei Darussalam
- People's Republic of China
- Hong Kong SAR
- Indonesia
- Korea
- Malaysia (Chair Ministry of Health)
- Philippines
- Saudi Arabia
- Singapore
- Chinese Taipei
- Thailand
- Vietnam





Asian Harmonization Working Party Purpose:

"... To study and recommend ways to harmonize regulation in the Asian region with global trends and to work in coordination with the Global Harmonization Task Force and APEC. ...





Asian Harmonization Working Party Purpose:

"... The AHWP will strive to:

Examine the use of quality system requirements around the world and prospects for adopting a quality system standard based on internationally recognized and accepted quality system standard for medical devices. ..."





Asian Harmonization Working Party Purpose (cont'd):

"... Work toward building a common regulatory consensus based on acceptance of international standards as the chief means of ensuring product safety and assurance.

Move toward recognition of a common audit that can be accepted throughout the Asian region. ..."

"... Work toward a harmonized system of medical device vigilance reporting for adoption within the region and information sharing.





Asian Harmonization Working Party

Purpose (cont'd):

"Work with the GHTF on technical harmonization efforts and seek representation as observers at their study groups. ..."

"... Facilitate the process of regional implementation of APEC initiatives for the medical devices and equipment sector."





Asian Harmonization Working Party (AHWP) Work program for 2005-2007

- Comparative study on existing medical device regulations in AHWP member economies
- Harmonization of definition, classification and nomenclature within AHWP
- Formalization of a post-marketing alert system
- Capacity building through training
- Work toward common submission dossier in alignment with ASEAN ACCSQ MDPWG
- Funding





Asian Harmonization Working Party (AHWP)

Asian Harmonization Working Party - Microsoft Internet Explorer provided by Guidant Corporation			
Asian Harmonization Working Party - Microsoft Internet Explorer provided by Guidant Corporation File Edit View Favorites Tools Help URL: http://www.asiahwp.org			
🚱 Back 🔹 🕥 - 🙁 😰 🏠 🔎 Search 🤺 Favorites 🤐 😥 😳 📓 🔹 🛄 😨			
Address 🙆 http:	//www.asiahwp.org/?page=article&ir=203	3	Go Links »
	AHWP	Asian Harmonization Working Party	
		WORKING TOWARDS MEDICAL DEVICE HARMONIZATION IN ASIA	
	Home Join Us Historical De	velopment Contact Us Sitemap Search: GO	
	Public Section:	The 11th Asian Harmonization Working Party (AHWP) Meeting	
	» Chairman's Message	AHWP Pre-Meeting Workshop	
	» Latest News	Date: 13 - 15 September 2006	
	» About AHWP	Venue: Olympic Parktel, Seoul, Korea	
	» Member Economies	Organized by: Asian Harmonization Working Party (AHWP)	
	» Secretariat	Hosted by:	
	» Technical Committee	Korea Food and Drug Administration (KFDA)	
	» Trade Related Issues	Sponsored by: Korea Medical Devices Industry Association (KMDIA)	
	» Trust Fund	Korea Health Industry Development Institute (KHIDI) American Chamber of Commerce (AMCHAM) of Korea	
	» Events	The 11th AHWP Meeting	
	» Web Resources	The 11th AHWP Meeting provides another forum for discussion on pertinent issues and commitment towards the convergence of medical devices regulatory requirements in the Asian region. It will	
	» Public Documents	review and discuss the strategies, activities, deliverables and timeframe to carry out the activities identified under the AHWP work program. The Meeting will be held on Friday, 15 September 2006 in	
	» Home	Seoul, Korea.	
		The AHWP Pre-Meeting Workshop A two-day Pre-meeting Workshop will be held on Wednesday, 13 September 2006 and Thursday, 14 September 2006 in conjunction with the Meeting. The Pre-Meeting Workshop is designed as an educational as well as information exchange forum on medical devices and medical devices regulatory requirements. Various pertinent topics relating to medical devices, medical devices regulatory system and efforts towards global harmonization of the regulatory system will be presented by internationally renowned experts. The topics to be covered include Conformity Assessment Procedure, STED, GMDN, Combination Products, Risk Management, Clinical Trials, Quality System; and Vigilance Reporting System.	
		For online registration, please proceed to the URL below: <u>http://www.kmdia.or.kr/ahwp/intro.htm</u>	_1
ē)			Internet
	🥭 🏠 🧿 🛛 🖉 Inbox - Micro		« O Ø 🕅 17:25



Combination Products







Asia-Pacific medical device regional regulatory harmonization initiatives







Pan American Health Organization

"RESOLVES:

2. To support the proposal to form an ad hoc group to promote and facilitate the medical devices harmonization processes in the Americas.

3. To urge the Member States to:(a) develop and strengthen their proc

(a) develop and strengthen their programs for the regulation of medical devices;

(b) promote and support the participation of their regulatory authorities at the general meetings of the Global Harmonization Task Force (GHTF) and those of its four study groups, while promoting the use of GHTF documents in their programs for the regulation of medical devices."

Source: Pan American Health Organization: 42nd Directing Council, 28 Sept. 2000 Provisional Summary Record of the Eighth Meeting



Asia-Pacific medical device regional regulatory harmonization initiatives





APEC funded regional regulatory training





APEC funded regional regulatory training





Asia-Pacific medical device regional regulatory harmonization initiatives





ASEAN ACCSQ MDPWG







-Oct-06



ASEAN Consultative Committee on Standards and Quality Medical Devices Product Working Group

 Mandate from ministers to remove technical barriers to trade, to provide medical industry in ASEAN with a better environment for growth, and to ensure faster access to safe and effective medical devices

- Emphasis on need to coordinate with GHTF and align regional regulatory framework with international practices
- ASEAN objective to promote harmonization of standards
- Accelerating economic integration toward establishment of Asian economic community



ASEAN Consultative Committee on Standards and Quality Medical Devices Product Working Group

- Chair: Malaysia; Co-Chair: Singapore
- Scope of activities:
 - Developing a common submission dossier template for product approval in ASEAN

 Explore feasibility of abridged approval process for devices which regulators of benchmarked countries or recognized regulators have approved

 Explore feasibility of adopting harmonized system of placement of medical devices into ASEAN markets, based on common approval process




ASEAN Consultative Committee on Standards and Quality Medical Devices Product Working Group

- Scope of activities (cont'd):
 - Formalize a post-marketing alert system for defective or unsafe medical devices
 - All ASEAN countries to consider joining AHWP and work in parallel with GHTF on technical harmonization efforts
- Industry invited to participate as observers
- Most recent meeting 14-16 Feb. 2006, Chiang Mai, Thailand



Asia-Pacific medical device regional regulatory harmonization initiatives





APEC Life Sciences Innovation Forum

"Life Sciences innovation was recognised as a critical area of growth and socio-economic development healthy people produce healthy economies. Productivity gains far outweigh the costs of developing innovative products. New product development and use adds significantly to longevity, wellness and economic potential.

Successful Life Sciences industry requires political leadership and commitment from the top and depends on the proper policy environment, public-private partnership, human capacity, and efficient and effective delivery of patient focused products and services. ...



Source: APEC Life Sciences Innovation Forum: http://www.apec.org/apec/apec_groups/other_apec_groups/life_sciences.html

APEC Life Sciences Innovation Forum

"Capacity building for the harmonization of standards and regulatory practices for bio-medical products and services according to international best practices where the need is most pressing and obstacles are the greatest."



Source: APEC Life Sciences Innovation Forum: http://www.apec.org/apec/apec_groups/other_apec_groups/life_sciences.html

Conclusions

 Regional and international regulatory harmonization supports global medical device product development and clinical trial strategies

- Regional harmonization initiatives underway
 - Opportunity for prospective harmonization
 - Need sustained political support and funding
 - Coordination would be helpful

 Initiatives can promote timely access of patients, clinicians, and health care systems to safe and effective medical device technology



GHTF Vision

Enhancing the health of the public worldwide and facilitating innovation by harmonizing the global regulatory environment





APEC funded regional regulatory training – Bangkok, 13-17 June 2005

- 201 regulators and industry representatives
 - 13 economies with developing regulatory systems
 - 15 APEC economies
 - 6 non-APEC economies
 - Regulators from APEC economies with
 - developing regulatory systems: 69
 - Industry representatives from APEC economies with developing regulatory systems: 104
 - Others (trainers, etc.): 28



In view of the emerging public health and population challenges,

In view of the regional objectives of promoting capacity building for medical device regulators,

In view of the industrial development policies of national governments and regional cooperative bodies, and ...



In view of the APEC LSIF objective of capacity building for harmonization of standards and regulatory practices for biomedical products according to international best practices where the need is most pressing and obstacles are greatest



Recommend to Ministers to promote the adoption of GHTF guidance documents in APEC member economies

consistent with local public health priorities

 in stages, from basic regulatory controls to more advanced and intensive controls as resources permit

 consider regional "pooling of competence" in conformity assessment



Recommend to Ministers to promote closer coordination between regional medical device regulatory harmonization initiatives



APEC funding and institutional support mechanisms should be considered in support of:

 Funding to continue and expand ACCSQ-MDWPG comparative study on medical device control in ASEAN member countries

 Financial support for ongoing work of AHWP and LAHWP

 Development and maintenance of expanded AHWP, ACCSQ-MDWPG, and LAHWP websites



APEC funding and institutional support mechanisms should be considered in support of (cont'd):

 More frequent regional training seminars, with greater numbers of participants from national regulatory authorities

- Development of "E-learning" tools
- Training for regulators on specific technologies
- Establishment of a "dense regulatory knowledge network" at regional levels



APEC funding and institutional support mechanisms should be considered in support of (cont'd):

 Collaborative development and promulgation of regional guidelines based on GHTF guidance documents and GMDN

 Support of pilot projects, e.g., evaluation of harmonized premarket conformity assessment dossier formats

 Promotion of adoption and recognition of international standards (ISO, IEC) without national deviations



APEC funding and institutional support mechanisms should be considered in support of (cont'd):

 Establishment and maintenance of regional Internet-based database and information exchange network for medical device adverse event/vigilance reports

 Pilot studies of regional mutual acceptance of results of premarket conformity assessments and/or results of regulatory audits

